BioSpace News Archive

Galmed Pharmaceuticals Ltd. today that the United States Patent and Trademark Office (USPTO) granted Galmed United States Patent 11,571,431 B2, which is expected to provide exclusivity of Aramchol meglumine salt until December 2034.

Lunit, in conjunction with Agfa HealthCare, announced the successful ‘GO LIVE’ of the breast imaging AI solution, Breast AI Analysis Package, at Dubai Academic Health Corporation Dubai Hospital.

Novaliq today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union.

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems TrueMark STI Select Panel, a polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium in one test, as well as RNase P, included as a human internal control.

Strateos, Inc. today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer.

AmerisourceBergen (AB), a global healthcare company, released its 2022 Environmental, Social and Governance (ESG) Summary Report.

Sonnet BioTherapeutics Holdings, Inc. today announced the pricing of an underwritten public offering of 13,888,888 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock.

Atsena Therapeutics today announced that positive interim data from the ongoing Phase I/II clinical trial of ATSN-101 will be presented at the 46th Annual Macula Society Meeting, which is being held February 15-18 in Miami, FL.

BridgeBio Pharma, Inc. today announced that members of the management team will participate in the following upcoming investor conferences.

Century Therapeutics, Inc. announced today that the first patient has been dosed in the first-in-human Phase 1 ELiPSE-1 trial evaluating CNTY-101 in patients with relapsed or refractory CD19 positive B-cell lymphomas.